Diffuse Large B-Cell Lymphoma

This is a type of lymphoma that grows quickly and affects many parts of the body. It starts in B-cells and the cells spread throughout the lymph system and other tissues. It's considered an aggressive type of lymphoma.

Condition

What people with Diffuse Large B-Cell Lymphoma report

Every report comes from a Lived member, sent anonymously.

Have you had Chemotherapy infusion for Diffuse Large B-Cell Lymphoma?

NameHow it went

About Diffuse Large B-Cell Lymphoma

What It Is

Diffuse large B-cell lymphoma (DLBCL) is a fast-growing cancer of B cells, the white blood cells that normally make antibodies to fight infection. It is the most common type of non-Hodgkin lymphoma in the United States, accounting for about 1 in 3 lymphomas, and it most often affects people in their 60s and older. DLBCL often first shows up as a growing lump in a lymph node in the neck, armpit or groin. It can also start deep inside the chest or abdomen, where it may cause a cough, breathlessness, belly swelling or a feeling of fullness after small meals, or in organs outside the lymph nodes, such as the stomach, intestines or bone. Some people have fevers without an infection, drenching night sweats and weight loss without trying, a combination doctors call B symptoms. Because it grows quickly, DLBCL is usually treated soon after diagnosis, unlike some slow-growing lymphomas that can be watched for years. It is also generally considered curable, and many people are cured by their first course of treatment.

Causes & Risk Factors

In most people, doctors cannot say why DLBCL developed. It begins when a B cell becomes abnormal and keeps dividing, producing more and more abnormal cells that build up in lymph nodes or other organs. Some factors make it more likely. Age is the most important: the typical age at diagnosis is about 67. A weakened immune system raises risk, including in people who take immune-suppressing medicines after an organ transplant, people with HIV and children born with certain inherited immune disorders. Autoimmune diseases such as rheumatoid arthritis, lupus and Sjögren disease are also linked to a higher risk, as is having a parent, sibling or child with non-Hodgkin lymphoma. Chemotherapy for an earlier cancer may raise the risk years later, and some studies suggest a link with chemicals such as benzene and certain weed and insect killers, although that research is not settled. DLBCL can also arise from a slow-growing lymphoma, most often follicular lymphoma, that changes into a faster-growing form. This is called transformation. These factors raise the odds of lymphoma; they do not mean a person caused it or could have prevented it.

How It's Diagnosed

Swollen lymph nodes are far more often caused by infection than by lymphoma, so a doctor will consider other explanations first. Blood tests can offer clues but cannot diagnose lymphoma. The diagnosis requires a biopsy: a surgeon removes all or part of an enlarged lymph node, or a needle guided by CT or ultrasound takes a sample from a deeper mass. A pathologist then examines the cells and runs lab tests on them to confirm the exact type of lymphoma, which matters because different lymphomas are treated very differently. Once DLBCL is confirmed, imaging, usually a PET/CT scan, shows where the lymphoma is. Doctors describe this as a stage. Stage I means one lymph node area or one spot in a single organ. Stage II means two or more node groups on the same side of the diaphragm, the muscle between the chest and the abdomen. Stage III means nodes on both sides of the diaphragm, and stage IV means the lymphoma has spread widely into an organ such as the bone marrow, liver or lungs. A large mass, called bulky disease, can change how stage II is treated. Some people also need a bone marrow biopsy, or a spinal tap if the brain or spinal cord may be involved. Doctors combine stage with the International Prognostic Index (IPI), which gives one point for each of five features: age over 60, stage III or IV, lymphoma in more than one organ outside the lymph nodes, needing a lot of help with daily activities, and a high blood level of LDH (lactate dehydrogenase, an enzyme that rises with the amount of lymphoma in the body). A score of 0 or 1 is low risk and a score of 4 or 5 is high risk. The score helps decide how intensive treatment should be. Before treatment starts, blood tests check for hepatitis B, hepatitis C and HIV, because these infections affect treatment choices. A heart scan, such as an echocardiogram, checks heart function because one of the main chemotherapy drugs can strain the heart.

Treatment Options

The goal of treatment is cure. For most people, the first treatment is R-CHOP, named for the initials of its drugs. It combines rituximab (Rituxan), an antibody that attaches to a marker called CD20 on B cells and helps destroy them, with four drugs: cyclophosphamide, doxorubicin and vincristine, which are chemotherapy, and prednisone, a steroid. R-CHOP is given as infusions in cycles three weeks apart. For lymphoma limited to one or two nearby node areas, three to six cycles are often given, sometimes followed by radiation to the affected area, especially when the mass was bulky. For more advanced disease, R-CHOP remains standard, and adults with an IPI score of 2 or higher may be offered Pola-R-CHP instead. It replaces vincristine with polatuzumab vedotin (Polivy), an antibody that carries a chemotherapy drug directly to lymphoma cells. A PET/CT scan after several cycles shows how well treatment is working. People at higher risk of the lymphoma returning in the brain and spinal cord may also receive chemotherapy injected into the spinal fluid or high-dose methotrexate, a chemotherapy drug that can reach that fluid from the bloodstream. People with heart problems or other serious illnesses may be offered a different regimen. Treatment has real costs. Chemotherapy temporarily lowers blood counts, which raises the risk of infection, bleeding and fatigue, and it can cause hair loss, mouth sores and nausea; these usually ease after treatment ends. Doxorubicin can damage the heart, and many of these drugs can affect fertility, which is worth raising before treatment begins. Reactions to rituximab are most likely during the first infusion, so it is given under close watch, and because it can reactivate an old hepatitis B infection, people are screened and monitored. When a large lymphoma breaks down quickly at the start of treatment, the released cell contents can overwhelm the kidneys (tumor lysis syndrome), so the team gives extra fluids and preventive medicines. If the lymphoma does not go away or comes back, further treatment can still lead to lasting control and, for some people, cure. Options include a different chemotherapy regimen followed by high-dose chemotherapy and a stem cell transplant, if the lymphoma responds and the person is fit enough. CAR T-cell therapy, in which a person's own T cells (a type of immune cell) are changed in a laboratory to attack the lymphoma and then infused back, is used when the lymphoma does not respond to first treatment or returns within about a year. Bispecific antibodies, which help the immune system recognize and kill lymphoma cells, other targeted drugs and clinical trials are further choices.

What to Expect

A first course of treatment usually takes a few months, with an infusion visit every three weeks and blood tests in between. Tiredness often builds across the cycles. In the days when white blood cells are lowest, infection is the main risk, so people are advised to wash their hands often, avoid people who are sick and follow food-safety precautions. Most short-term side effects fade after treatment ends, though energy can take longer to return. Outlook depends heavily on stage and IPI score. In the United States, about two thirds of people diagnosed with DLBCL are alive five years later, compared with similar people without the disease, and about 80 percent when it is found at stage I. These population figures cannot predict what will happen to any one person, and they include people diagnosed before some newer treatments were available. After treatment, follow-up visits are usually every few months for the first year or so, then less often, with an exam, blood tests and scans when needed. Lymphoma can come back, sometimes years later, and some treatment effects, such as heart problems, may appear long after treatment ends. Survivors also have a higher risk of some other cancers, so routine cancer screening and checkups remain important.

When to Seek Help

See a doctor about a lymph node lump that keeps growing, or about fevers without an obvious infection, drenching night sweats or weight loss without trying. After treatment, tell your care team about a new lump or the return of these symptoms instead of waiting for the next scheduled visit. During chemotherapy, call your care team right away, at any hour, for a temperature of 100.5°F (38°C) or higher, shaking chills or other signs of infection, since infections when white blood cells are low can become life threatening quickly. Check with the team before taking medicine to bring a fever down, because it can hide the warning sign. Seek emergency care for new swelling of the face, neck, arms or upper chest together with trouble breathing. A lymphoma in the chest can press on the large vein that drains the head and arms, and this needs treatment right away.

Questions to Ask Your Doctor

  1. 1.What stage is my lymphoma and what is my IPI score, and how do they affect my treatment and chances of cure?
  2. 2.Is R-CHOP or Pola-R-CHP the better fit for me, how many cycles will I need, and will I need radiation or treatment to protect the brain and spinal cord?
  3. 3.Which side effects should I prepare for, and should I take steps to preserve fertility before starting?
  4. 4.How will we know whether treatment has worked, and what follow-up will I need afterward?
  5. 5.If the lymphoma does not respond or comes back, what would my next options be, and is a clinical trial worth considering?

Last reviewed • Oct 2026

Educational content, not medical advice.